SCHEMBL1963173

SCHEMBL1963173

CSc1ccc(C(=O)c2cc3cccnc3n2S(=O)(=O)c2ccccc2)cc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
PTGDR2 Q9Y5Y4 3/20 0.40
HDAC3 O15379 5/20 0.38
HDAC4 P56524 5/20 0.38
HDAC1 Q13547 5/20 0.38
HDAC7 Q8WUI4 5/20 0.38
HDAC2 Q92769 5/20 0.38
HDAC10 Q969S8 5/20 0.38
HDAC11 Q96DB2 5/20 0.38
HDAC8 Q9BY41 5/20 0.38
HDAC6 Q9UBN7 5/20 0.38
HDAC9 Q9UKV0 5/20 0.38
HDAC5 Q9UQL6 5/20 0.38
CYP2C19 P33261 1/20 0.36
HSD11B1 P28845 2/20 0.36
RECQL P46063 1/20 0.34
TRPV1 Q8NER1 1/20 0.33
VNN1 O95497 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1961237 0.85 HDAC3 (0.42) ALDH1A1LMNAMAPTHDAC3HDAC4
SCHEMBL1959020 0.83 MAPT (0.50) ALDH1A1LMNAMAPTPTGDR2HDAC3
SCHEMBL1962390 0.80 RECQL (0.44) ALDH1A1LMNAMAPTPTGDR2CYP2C19
SCHEMBL5716793 0.75 HDAC3 (0.55) ALDH1A1LMNAMAPTPTGDR2HDAC3
SCHEMBL1772350 0.74 LMNA (0.53) ALDH1A1LMNAMAPTPTGDR2CYP2C19
SCHEMBL17927616 0.74 MAPT (0.47) ALDH1A1LMNAMAPTPTGDR2HDAC3
SCHEMBL4876447 0.74 ALDH1A1 (0.55) ALDH1A1LMNAMAPTPTGDR2CYP2C19
SCHEMBL5716825 0.73 TUBB4A (0.53) ALDH1A1LMNAMAPTPTGDR2HDAC3
SCHEMBL14053495 0.73 ALDH1A1 (0.55) ALDH1A1LMNAMAPTPTGDR2HDAC3
SCHEMBL27700600 0.72 ALDH1A1 (0.53) ALDH1A1LMNAMAPTPTGDR2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 ALDH1A1 769/4885LMNA 4695/4885MAPT 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.